483
Zhejiang Huahai PharmaceuticalFDA 483 - Zhejiang Huahai Pharmaceutical - August 03, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Zhejiang Huahai Pharmaceutical Co., Ltd. revealed significant deficiencies across its quality, production, and laboratory systems. The firm demonstrated inadequate change control, insufficient process and cleaning validation, and poor deviation investigation practices. These issues indicate a systemic failure to ensure the quality and purity of Active Pharmaceutical Ingredients (APIs) manufactured at the facility.
Open in Dashboard
ID · 52b9509e-bd30-4536-a4de-b2064ff256b1